Loeys–Dietz Syndrome 6 (SMAD2-Related) — Disease Characteristics Research Report

Scope and evidence grading. Loeys–Dietz syndrome type 6 (LDS6) is exceptionally rare, and “LDS6” is not used consistently. This report therefore distinguishes: [Direct LDS6] evidence involving germline SMAD2 variants; [Pan-LDS] evidence from genetically heterogeneous Loeys–Dietz syndrome; and [HTAD/model] evidence extrapolated from hereditary thoracic aortic disease or other TGF-β-pathway LDS models. Quantitative phenotype frequencies, penetrance, treatment response, and prognosis specific to LDS6 are largely unavailable.

A compact knowledge-base summary follows.

Table: This table summarizes the best-supported findings for SMAD2-related Loeys-Dietz syndrome 6, while clearly separating subtype-specific evidence from broader Loeys-Dietz syndrome and hereditary thoracic aortic disease extrapolations. It is useful as a compact knowledge-base scaffold for curation and evidence-gap tracking.

1. Disease information

Definition

[Direct LDS6] LDS6 is a Mendelian, autosomal-dominant syndromic aortopathy caused by a heterozygous pathogenic variant in SMAD2, which encodes a receptor-regulated intracellular effector of TGF-β signaling. Its defining clinical risk is progressive arterial disease—particularly thoracic/aortic-root aneurysm, dissection, or rupture—with variable craniofacial, skeletal, cutaneous, and cardiac-valvular connective-tissue manifestations. A 2023 review states that “type 6 [is] determined by the SMAD2 mutation” and attributes the initial association to families with aneurysm/dissection and abnormal aortic-wall SMAD2 expression. (asta2023geneticbasisnew pages 3-5)

Because SMAD2-related disease has been reported only rarely, some authors use “SMAD2-related syndromic thoracic aortic aneurysm and dissection” rather than LDS6. A 2024 dissertation reviewing LDS disease models explicitly notes that “LDS type 6 is not consistently used in literature.” (ebeling2024differentiationpurificationand pages 9-11)

Identifiers and synonyms

• MONDO: No subtype-specific MONDO identifier was verified in the retrieved evidence. The broader Loeys–Dietz syndrome term is MONDO:0018954.
• MeSH: D055947, Loeys-Dietz Syndrome, broader disease term. (NCT05472519 chunk 1)
• OMIM: Broader LDS entries cited by the retrieved literature include 609192 and 610168, historically corresponding to receptor-defined LDS forms rather than a confirmed subtype-specific LDS6 record. These should not be assigned to LDS6 without independent OMIM verification. (ebeling2024differentiationpurificationand pages 9-11)
• ICD-10: No dedicated LDS6 code. LDS is commonly grouped under Q87.4 in the retrieved source; local coding may instead use congenital malformation/connective-tissue or aortic-disease codes. (ebeling2024differentiationpurificationand pages 9-11)
• ICD-11: No verified subtype-specific code retrieved.
• Synonyms: Loeys-Dietz syndrome type 6, LDS type 6, LDS6, SMAD2-related Loeys-Dietz syndrome, SMAD2-related syndromic aortopathy, SMAD2-related hereditary thoracic aortic disease.
• Gene: SMAD2, Ensembl ENSG00000175387. Open Targets reports five genetic evidence items and an LDS–SMAD2 association score of approximately 0.76. (OpenTargets Search: Loeys-Dietz syndrome-SMAD2)

Data provenance

The entry is based primarily on aggregated disease resources, published families/case series, reviews, and registries, not individual-level EHR data. GenTAC collected longitudinal clinical data and biospecimens from 3,706 people with genetically triggered aortic conditions, including LDS, but the retrieved record does not provide an LDS6 subgroup. (NCT01322165 chunk 1)

2. Etiology

Causal factor and genetic risk

[Direct LDS6] The primary cause is a germline heterozygous pathogenic/likely pathogenic SMAD2 variant. Open Targets/Genomics England evidence supports monoallelic inheritance and includes stop-gained and splice-acceptor variant records, although complete HGVS descriptions were not present in the retrieved material. (OpenTargets Search: Loeys-Dietz syndrome-SMAD2)

Reported pathogenic classes include missense, nonsense/truncating, and splice-disrupting variants. The 2023 review particularly associates missense and nonsense SMAD2 variants with LDS6. Exact domain-specific genotype–phenotype relationships remain insufficiently established. (asta2023geneticbasisnew pages 3-5)

The strongest risk factors are therefore:

1. A pathogenic germline SMAD2 allele.
2. An affected first-degree relative or family history of thoracic aortic aneurysm/dissection or sudden unexplained death.
3. Established aneurysm, rapid arterial growth, hypertension, and pregnancy-related hemodynamic stress—clinically important modifiers extrapolated from pan-LDS/HTAD.

Environmental and lifestyle risk factors

No environmental exposure causes LDS6. Hypertension, stimulant or vasoconstrictor exposure, smoking, and high-static/straining exercise may add mechanical stress to a genetically vulnerable arterial wall; however, no LDS6-specific effect sizes are available. Current HTAD management emphasizes blood-pressure control, avoidance of stimulants/vasoconstrictors, and exercise restriction. (spaziani2024hereditarythoracicaortic pages 7-9)

No infectious trigger is recognized. LDS6 is not contagious or zoonotic.

Protective factors

No genetically protective SMAD2 allele or validated modifier gene has been established. Clinically protective measures are secondary/tertiary rather than etiologic: early molecular diagnosis, serial whole-arterial imaging, strict blood-pressure control, avoidance of high-strain activity, and appropriately timed prophylactic surgery. Evidence for beta-blockers or angiotensin-receptor blockers in LDS is indirect; no randomized LDS trial has shown reduced dissection risk. (spaziani2024hereditarythoracicaortic pages 9-10)

Gene–environment interaction

The working model is that SMAD2 dysfunction lowers arterial resilience while blood pressure, pulse-wave stress, pregnancy, and intense isometric exertion increase wall loading. This interaction may accelerate dilation or precipitate dissection, but it has not been quantified for LDS6.

3. Phenotypes

The following are reasonable curation targets. Unless stated otherwise, frequencies and age distributions are unknown for LDS6.

Vascular and cardiac

• Aortic-root/ascending thoracic aortic dilatation or aneurysm — clinical sign/imaging abnormality; congenital through adult onset; progressive and potentially severe. Suggested HPO: Aortic root dilatation, Thoracic aortic aneurysm.
• Aortic dissection/rupture — acute vascular complication superimposed on lifelong susceptibility; life-threatening. HPO: Aortic dissection, Aortic rupture.
• Aneurysms/dissections outside the proximal aorta and arterial tortuosity — expected within the broader LDS phenotype but LDS6-specific distribution is unresolved. HPO: Arterial tortuosity, Generalized arterial tortuosity, Arterial aneurysm.
• Mitral-valve disease and possibly aortic regurgitation — HPO: Mitral valve prolapse, Mitral regurgitation, Aortic regurgitation. The literature associates SMAD2-mutant families primarily with aneurysm/dissection, while valvular manifestations are better documented across LDS. (asta2023geneticbasisnew pages 3-5)

A pan-LDS neonatal example illustrates that disease can be evident at birth: a TGFBR2-positive newborn had a 16–17-mm aortic root with z-scores of +7.46 to +8.65 and tortuous major branches. This is not LDS6 evidence but demonstrates the possible congenital end of the LDS spectrum. (zaza2022cleftpalateand pages 2-5)

Craniofacial, skeletal, and cutaneous

Possible features include:

• Hypertelorism — HPO: Hypertelorism.
• Bifid uvula or cleft palate — HPO: Bifid uvula, Cleft palate.
• Arachnodactyly, joint hypermobility or contractures, scoliosis, pectus deformity, and clubfoot — corresponding HPO terms should be assigned when observed.
• Translucent/soft skin, easy bruising, or abnormal scarring — pan-LDS features; use phenotype-specific HPO terms rather than assuming presence.

These features are diagnostically supportive but neither necessary nor sufficient for LDS6. Their frequency in SMAD2-positive individuals is unknown. (asta2023geneticbasisnew pages 3-5, zaza2022cleftpalateand pages 2-5)

Allergic, gastrointestinal, neurologic, and behavioral features

Asthma, eczema, food allergy, elevated IgE/eosinophilia, eosinophilic gastrointestinal disease, and inflammatory bowel disease occur in pan-LDS, especially receptor-associated LDS, but have not been established as defining LDS6 features. The completed I-LoDiS study enrolled only TGFBR1/TGFBR2-positive participants, so its findings should not be directly transferred to SMAD2-related disease. (NCT05472519 chunk 1)

No characteristic behavioral or psychiatric phenotype, laboratory abnormality, or neurodevelopmental syndrome is established for LDS6.

Quality of life

No LDS6-specific EQ-5D, SF-36, PROMIS, or disease-specific patient-reported outcome data were found. Likely burdens include anxiety about dissection, repeated imaging, exercise and pregnancy restrictions, chronic musculoskeletal symptoms, and recovery from major vascular surgery. These should be recorded as anticipated consequences, not measured LDS6 statistics.

4. Genetic and molecular information

Gene and protein

• Gene: SMAD2, HGNC-approved symbol; chromosome 18q21.1.
• Protein: Mothers against decapentaplegic homolog 2/SMAD family member 2, a receptor-regulated SMAD.
• Function: Following TGFBR1-mediated phosphorylation, SMAD2 associates with SMAD3/SMAD4-containing complexes, enters the nucleus, and regulates transcription. (liu2025anoveltgfbr2 pages 7-8)

Variant interpretation

Testing laboratories should classify variants using ACMG/AMP criteria. Evidence expected for pathogenicity includes rarity/absence in population databases, segregation or de novo occurrence, predicted loss of function where applicable, location in a critical functional domain, and validated functional impairment. A VUS must not by itself establish LDS6 or direct prophylactic surgery.

Open Targets summarizes stop-gained and splice-acceptor disease records and monoallelic inheritance evidence, but the retrieved sources do not provide a complete curated list of SMAD2 HGVS variants or their gnomAD frequencies. (OpenTargets Search: Loeys-Dietz syndrome-SMAD2)

• Origin: Germline; somatic SMAD2 variants in cancer are not the cause of constitutional LDS6.
• Mechanistic class: Likely loss of normal canonical signaling, dominant-negative effects for some alleles, or haploinsufficiency for truncating/splice variants. Variant-specific mechanisms require functional confirmation.
• Structural variants: Large deletions/rearrangements disrupting SMAD2 are biologically plausible; no recurrent LDS6 chromosomal abnormality was established in the retrieved evidence.
• Modifier genes/epigenetics: No validated LDS6 modifier gene, methylation signature, or clinical epigenetic biomarker was found.

5. Environmental information

No toxin, radiation exposure, occupational agent, diet, infection, alcohol use, or smoking exposure is known to initiate LDS6. Smoking and uncontrolled hypertension should nevertheless be minimized because of general adverse vascular effects. Contact/collision sports, heavy weightlifting, intense isometric exercise, and activities requiring Valsalva maneuvers are generally restricted in heritable aortopathy; recommendations should be individualized to arterial dimensions, prior surgery, and blood-pressure response. (spaziani2024hereditarythoracicaortic pages 7-9)

6. Mechanism and pathophysiology

Causal chain

1. Upstream trigger: constitutional heterozygous SMAD2 pathogenic variant.
2. Primary biochemical defect: altered transmission of signals from activated TGFBR1/2 through phosphorylated SMAD2/3 complexes to nuclear transcriptional programs.
3. Cellular dysfunction: disturbed vascular smooth-muscle-cell differentiation/contractile homeostasis, stress responses, and communication with extracellular matrix, endothelial cells, fibroblasts, and immune cells.
4. Tissue remodeling: reduced elastic integrity, diffuse medial degeneration, elastic-fiber fragmentation, collagen and amorphous extracellular-matrix accumulation, and maladaptive matrix turnover.
5. Biomechanical consequence: progressive arterial-wall weakening and altered compliance.
6. Clinical manifestations: aortic-root/arterial dilatation → aneurysm → dissection or rupture; associated valve, craniofacial, skeletal, and cutaneous abnormalities reflect broader developmental TGF-β dysregulation. (asta2023geneticbasisnew pages 3-5)

The signaling paradox

TGF-β-pathway mutations may reduce ligand-induced signaling cell-autonomously yet coexist with increased tissue pSMAD2/3 at sites of aneurysm. In a Tgfbr1 LDS mouse, second-heart-field-derived aortic-root VSMCs had defective ligand-induced pSmad2/3, while diseased aortic-root tissue later showed localized increases in pSmad2/3 and TGF-β1/TGF-β3 that tracked with dilation. This supports secondary compensatory or non-cell-autonomous signaling rather than a simple global “gain” or “loss” model. (macfarlane2019lineagespecificeventsunderlie pages 2-5)

Cells, tissues, and ontology suggestions

• CL: vascular smooth muscle cell; endothelial cell; fibroblast; macrophage; T lymphocyte.
• GO Biological Process: transforming growth factor beta receptor signaling pathway; SMAD protein signal transduction; regulation of transcription by RNA polymerase II; extracellular matrix organization; elastic fiber assembly; smooth muscle cell differentiation; response to mechanical stimulus.
• GO Cellular Component: cytosol, nucleus, SMAD protein complex, receptor complex, extracellular matrix.

Molecular profiling and advanced technologies

No LDS6-specific single-cell, spatial-transcriptomic, proteomic, metabolomic, or lipidomic signature was found. Broader ascending-aortic studies report candidate circulating markers such as MMP-1/2/3/9, IL-6, GDF-15, miR-574-5p, C18-ceramide, aggrecan, and alpha-2-HS-glycoprotein, but none is validated for diagnosing or forecasting LDS6. (ganizada2024unveilingcellularand pages 14-15)

Patient-specific iPSC-derived endothelial cells are being developed for LDS modeling, offering a platform for genotype-specific endothelial phenotyping and drug testing. The retrieved 2024 work is methodological and does not establish a validated LDS6 biomarker or treatment. (ebeling2024differentiationpurificationand pages 9-11)

7. Anatomical structures affected

Organ/system level

• Primary: aortic root and ascending thoracic aorta; potentially the entire aorta and medium/large arterial tree.
• Secondary: heart valves; craniofacial skeleton and palate; axial/appendicular skeleton; skin and connective tissues.
• Systems: cardiovascular, musculoskeletal, craniofacial, integumentary; possible allergic/gastrointestinal involvement based on pan-LDS.

UBERON suggestions

Aortic root, ascending aorta, aortic arch, descending thoracic aorta, abdominal aorta, arterial wall, tunica media of artery, heart valve, palate, skin, vertebral column.

Aortic medial VSMCs are the principal implicated cell population. The relevant subcellular route spans plasma-membrane TGF-β receptor complexes, cytosolic SMAD phosphorylation/complex assembly, and nuclear transcription. No characteristic lateralization exists; vascular and skeletal findings may be bilateral or asymmetric depending on manifestation.

8. Temporal development

LDS6 is a congenital genetic condition with lifelong risk, even when no abnormality is visible at birth. Clinical onset ranges from prenatal/neonatal aortic dilation to childhood or adult discovery of aneurysm/dissection. Progression is chronic but highly variable; acute dissection is a catastrophic event superimposed on this chronic substrate.

No validated LDS6 staging system exists. A practical clinical course is:

1. Genotype-positive/no detectable arterial disease.
2. Stable or enlarging arterial tortuosity/dilatation.
3. Clinically significant aneurysm or rapid growth.
4. Dissection/rupture or prophylactic/emergency repair.
5. Lifelong post-repair surveillance for residual native-vessel disease.

There is no spontaneous remission. Critical intervention windows are before dissection, during family cascade screening, after detection of rapid growth, and before/during pregnancy. Pan-LDS literature reports nonpenetrance and mosaicism, underscoring that a normal early examination does not eliminate later risk. (zaza2022cleftpalateand pages 2-5)

9. Inheritance and population

Inheritance

• Pattern: autosomal dominant/monoallelic.
• Recurrence: an affected heterozygous individual has a 50% probability of transmitting the variant in each pregnancy.
• De novo disease: Across LDS, approximately 25% have an affected parent and the remainder are described as de novo; another retrieved review states roughly 75% are de novo. These are pan-LDS estimates, not LDS6-specific rates. (ebeling2024differentiationpurificationand pages 9-11, zaza2022cleftpalateand pages 2-5)
• Penetrance: incompletely defined and probably age dependent; nonpenetrance has been reported across LDS.
• Expressivity: markedly variable.
• Anticipation: not established.
• Germline mosaicism: theoretically relevant to apparently de novo recurrence, but no LDS6 rate is available.
• Founder effects, consanguinity, carrier frequency: none established; consanguinity is not expected to drive an autosomal-dominant disorder.

Epidemiology

LDS overall has been estimated at <1 in 100,000 or approximately 1 in 25,000–100,000, but robust population-based incidence and prevalence are lacking. A recent summary estimated SMAD2/LDS6 at 1–5% of LDS, which is an approximate relative fraction rather than a population prevalence. (ebeling2024differentiationpurificationand pages 9-11, NCT05472519 chunk 1)

No reproducible ethnic, geographic, sex, or founder enrichment has been established for LDS6. All sexes can be affected. Pregnancy creates an additional vascular/uterine risk for affected women, while the germline transmission probability is sex independent.

10. Diagnostics

Clinical evaluation

Diagnosis begins with personal/family history, three-generation pedigree, physical examination, and cardiovascular imaging. Suspicion should increase with early-onset aortic aneurysm/dissection, arterial tortuosity, bifid uvula/cleft palate, hypertelorism, marfanoid skeletal features, or a family history of sudden aortic death.

Imaging

• Transthoracic echocardiography: first-line measurement of aortic root/ascending aorta and valve function.
• CT angiography: rapid, high-resolution evaluation of the entire aorta and branch vessels; useful for acute disease and surgical planning but entails radiation/contrast.
• CMR/MRA: preferred for repeated longitudinal imaging in many children and young adults because it avoids ionizing radiation and can characterize the full aorta and hemodynamics. (asta2023geneticbasisnew pages 5-8, spaziani2024hereditarythoracicaortic pages 7-9)

Whole-arterial baseline imaging is important because echocardiography does not visualize every vulnerable segment. Imaging intervals should be individualized by genotype, age, dimensions, growth, family history, and prior surgery.

Genetic testing

1. Use a comprehensive heritable thoracic aortic disease panel including at least SMAD2, TGFBR1, TGFBR2, SMAD3, TGFB2, TGFB3, FBN1, COL3A1, ACTA2, MYH11, MYLK, LOX, PRKG1, and other validated HTAD genes.
2. Ensure sequencing plus deletion/duplication analysis.
3. Use exome or genome sequencing when panel testing is negative, phenotype is atypical, or structural/noncoding disease is suspected.
4. Confirm candidate variants and perform segregation/de novo analysis where possible.
5. Offer targeted cascade testing to relatives when a pathogenic familial variant is identified. If testing is negative or yields only a VUS, at-risk relatives may still require imaging based on family history. (asta2023geneticbasisnew pages 5-8)

CMA, karyotype, or FISH is not first-line for isolated suspected LDS6 but may be appropriate for syndromic developmental abnormalities or suspected larger rearrangements. Mitochondrial and repeat-expansion testing are not indicated. RNA sequencing may help resolve splice variants but is not standard primary diagnosis.

Differential diagnosis

• Other LDS subtypes: TGFBR1, TGFBR2, SMAD3, TGFB2, TGFB3.
• Marfan syndrome: FBN1, commonly ectopia lentis and classic Ghent phenotype.
• Vascular Ehlers–Danlos syndrome: COL3A1, marked tissue/arterial fragility.
• Shprintzen–Goldberg syndrome: SKI, craniosynostosis and developmental phenotype.
• Arterial tortuosity syndrome: SLC2A10, autosomal recessive.
• Familial nonsyndromic HTAD and bicuspid-aortic-valve aortopathy.

No single biochemical blood test or histopathologic criterion diagnoses LDS6. Candidate circulating ATAA biomarkers remain investigational. (ganizada2024unveilingcellularand pages 14-15)

11. Outcome and prognosis

The principal morbidity and mortality arise from aortic or arterial dissection/rupture, emergency surgery, stroke/malperfusion, valve disease, and repeated vascular interventions. Untreated acute type-A dissection is highly lethal; a general aortic-disease source cited mortality of 54% untreated versus 12–26% after surgery, but these are not LDS6-specific figures. (ebeling2024differentiationpurificationand pages 9-11)

No LDS6-specific life expectancy, 5-/10-year survival, mortality rate, or validated prognostic model was found. Prognosis is expected to improve substantially with early diagnosis, blood-pressure control, surveillance, and prophylactic repair. Adverse prognostic factors likely include early or diffuse arterial disease, rapid enlargement, family history of dissection at small diameter, uncontrolled hypertension, pregnancy, and residual native aorta after repair. These are clinically plausible pan-HTAD factors rather than quantified LDS6 predictors.

No validated prognostic biomarker exists. Aortic diameter and growth remain central but imperfect risk measures.

12. Treatment

Medical therapy

No medication corrects the germline defect, and no randomized trial has demonstrated reduced aortic growth or dissection specifically in LDS or LDS6. Current practice extrapolates from Marfan syndrome and mechanistic models:

• Beta-blocker—reduces heart rate, blood pressure, and pulsatile wall stress.
• Angiotensin II receptor blocker, commonly losartan—reduces blood pressure and may influence maladaptive TGF-β/ERK signaling.
• ACE inhibitor—alternative/additional blood-pressure control.

A 2024 HTAD review concludes that ARBs, beta-blockers, or ACE inhibitors are reasonable to lessen hemodynamic stress and that prophylactic ARB use may be considered in genotype-positive LDS with relevant family/variant history, while explicitly acknowledging the absence of LDS efficacy studies. (spaziani2024hereditarythoracicaortic pages 9-10)

Suggested NCIT-style intervention concepts: Beta Adrenergic Blocker, Angiotensin II Receptor Antagonist, Losartan, Angiotensin-Converting Enzyme Inhibitor, Antihypertensive Therapy.

Doxycycline, statins, MMP inhibition, direct TGF-β inhibition, and other pathway-directed agents remain experimental for inherited aortopathy and should not be represented as established LDS6 treatment. Calcium-channel blockers should be used cautiously in syndromic aortopathy. (spaziani2024hereditarythoracicaortic pages 9-10)

Surgery

Elective valve-sparing aortic-root replacement or composite graft replacement is the definitive preventive intervention when risk becomes unacceptable. Decisions should be genotype- and patient-specific, incorporating absolute diameter, body size/z-score, growth rate, family history, valve function, pregnancy plans, and surgical expertise. The retrieved sources did not provide a validated SMAD2-specific threshold; therefore, generic 40–50-mm statements must not be treated as an LDS6 rule. (ebeling2024differentiationpurificationand pages 9-11)

Suggested NCIT concepts: Aortic Root Replacement, Valve-Sparing Aortic Root Replacement, Aortic Aneurysm Repair, Vascular Surgery.

Supportive care

Multidisciplinary care may include cardiology/aortopathy, cardiovascular surgery, medical genetics, maternal–fetal medicine, orthopedics, craniofacial/ENT, allergy/gastroenterology, physiotherapy, occupational therapy, pain management, and psychological support.

Advanced and experimental therapeutics

No approved gene therapy, CRISPR treatment, cell therapy, RNA therapy, or LDS6-specific targeted biologic was found. Editing a dominant SMAD2 allele would require allele-specific safety, delivery to the arterial wall, and careful avoidance of disrupting essential TGF-β functions.

Trials and real-world implementations

• GenTAC, NCT01322165: completed prospective registry; 3,706 participants across genetic aortopathies; longitudinal outcomes and biospecimens. (NCT01322165 chunk 1)
• I-LoDiS, NCT05472519: completed 2023, 60 participants; investigated immune populations and pSMAD2/3, but eligibility was restricted to TGFBR1/TGFBR2-positive LDS and therefore does not directly study LDS6. (NCT05472519 chunk 1)
• No LDS6-specific therapeutic interventional trial was identified.

13. Prevention

Primary prevention

The inherited variant cannot presently be prevented after conception. Reproductive options after identification of a familial pathogenic variant include genetic counseling, preimplantation genetic testing, chorionic-villus sampling, or amniocentesis. Prenatal ultrasound has low sensitivity for many LDS manifestations, though severe prenatal aortic dilation may occasionally be detected. (zaza2022cleftpalateand pages 2-5)

Secondary prevention

• Cascade genetic testing and baseline cardiovascular imaging of first-degree relatives.
• Early whole-aorta/arterial imaging in genotype-positive individuals.
• Regular blood-pressure assessment and treatment.
• Pregnancy risk assessment before conception.

Tertiary prevention

• Serial multimodality imaging.
• Medical reduction of hemodynamic stress.
• Avoidance of smoking, stimulants/vasoconstrictors, collision sports, heavy isometric exertion, and Valsalva-heavy lifting.
• Timely prophylactic vascular surgery.
• Lifelong surveillance after repair because unrepaired arterial segments remain at risk. (spaziani2024hereditarythoracicaortic pages 7-9, spaziani2024hereditarythoracicaortic pages 9-10)

No immunization, infectious prophylaxis, newborn biochemical screening, or population-wide screening program is applicable. Targeted familial screening is the appropriate public-health strategy.

14. Other species and natural disease

No well-established naturally occurring veterinary LDS6 caused by an orthologous SMAD2 variant was identified. SMAD2 is evolutionarily conserved across vertebrates, consistent with conserved TGF-β developmental and vascular functions, but conservation alone does not demonstrate natural disease.

• Human: Homo sapiens, NCBI Taxonomy 9606.
• Common experimental comparison species include Mus musculus (10090) and Danio rerio (7955).
• No breed-specific VBO annotation, veterinary prevalence, cross-species transmission, or zoonotic potential applies.

15. Model organisms and experimental systems

Available/related models

No well-characterized Smad2 knock-in model reproducing a specific human LDS6 allele was found in the retrieved literature. Because complete Smad2 loss has major developmental consequences, constitutive knockout models may poorly represent viable heterozygous human LDS6 and conditional or allele-specific models are preferable.

A highly informative Tgfbr1-M318R/+ LDS mouse develops aortic-root dilation and demonstrates lineage-specific pathogenesis: second-heart-field-derived VSMCs show deficient TGF-β-induced pSmad2/3 and target-gene activation, while later diseased tissue exhibits localized excess pSmad2/3 and TGF-β ligand. This recapitulates LDS pathway biology but is not a SMAD2/LDS6 model. (macfarlane2019lineagespecificeventsunderlie pages 2-5)

Cellular models

• Patient fibroblasts and induced myofibroblasts.
• iPSC-derived vascular smooth-muscle cells.
• iPSC-derived endothelial cells.
• Isogenic CRISPR-corrected or knock-in pairs.
• Aortic organoids/tissue-engineered vessels.

A 2024 LDS iPSC-endothelial methodology project highlights these systems as alternatives to rodent models with limited clinical transferability. Applications include variant functional classification, cell-lineage studies, extracellular-matrix and mechanotransduction assays, and drug screening. (ebeling2024differentiationpurificationand pages 9-11)

Model limitations

Models must reproduce heterozygosity, relevant SMAD2 isoform/domain effects, human arterial-cell lineage, pulsatile mechanical loading, and long disease latency. TGFBR1/TGFBR2/SMAD3 or Marfan models illuminate shared pathways but cannot establish an LDS6-specific phenotype or treatment response.

Recent developments, authoritative interpretation, and key gaps

Recent 2023–2024 work emphasizes three developments: expanding gene-informed HTAD diagnosis, increasingly comprehensive CT/CMR surveillance, and cell/lineage-specific modeling rather than treating TGF-β signaling as uniformly increased or decreased. MRI/CMR is particularly valuable for repeated imaging because it avoids ionizing radiation and supports biomechanical measurements; next-generation sequencing enables cascade diagnosis across genetically heterogeneous aortopathies. (asta2023geneticbasisnew pages 5-8, spaziani2024hereditarythoracicaortic pages 7-9)

The most important expert-level conclusion is that SMAD2 is credibly associated with Loeys–Dietz-spectrum aortopathy, but LDS6 remains too sparsely described for independent evidence-based thresholds or outcome estimates. Open Targets supports the gene–disease association, yet current surveillance and treatment are necessarily extrapolated from broader LDS/HTAD practice. (OpenTargets Search: Loeys-Dietz syndrome-SMAD2)

Priority research needs are: an international SMAD2 registry; standardized variant and domain annotation; age-specific penetrance and phenotype frequencies; whole-arterial natural history; pregnancy outcomes; patient-derived VSMC/endothelial and allele-specific animal models; validated circulating/imaging biomarkers; and genotype-specific treatment and surgical-threshold studies.

Selected dated sources and URLs

1. Asta L, et al. Genetic Basis, New Diagnostic Approaches, and Updated Therapeutic Strategies of the Syndromic Aortic Diseases. Published August 2023. DOI/URL: https://doi.org/10.3390/ijerph20166615. (asta2023geneticbasisnew pages 5-8, asta2023geneticbasisnew pages 3-5)
2. Spaziani G, et al. Hereditary Thoracic Aortic Diseases. Published January 2024. DOI/URL: https://doi.org/10.3390/diagnostics14010112. (spaziani2024hereditarythoracicaortic pages 7-9, spaziani2024hereditarythoracicaortic pages 9-10)
3. Ganizada BH, et al. Unveiling cellular and molecular aspects of ascending thoracic aortic aneurysms and dissections. Published May 2024. DOI/URL: https://doi.org/10.1007/s00395-024-01053-1. (ganizada2024unveilingcellularand pages 14-15)
4. MacFarlane EG, et al. Lineage-specific events underlie aortic root aneurysm pathogenesis in Loeys-Dietz syndrome. Published January 2019. DOI/URL: https://doi.org/10.1172/JCI123547. (macfarlane2019lineagespecificeventsunderlie pages 2-5)
5. Zaza P, et al. Cleft Palate and Aortic Dilatation as Clues for Loeys–Dietz Syndrome. Published August 2022. DOI/URL: https://doi.org/10.3390/children9091290. (zaza2022cleftpalateand pages 2-5)
6. ClinicalTrials.gov NCT05472519, Immunopathology of Loeys-Dietz Syndrome, completed June 7, 2023: https://clinicaltrials.gov/study/NCT05472519. (NCT05472519 chunk 1)
7. ClinicalTrials.gov NCT01322165, GenTAC Registry, completed September 2016: https://clinicaltrials.gov/study/NCT01322165. (NCT01322165 chunk 1)

Abstract/direct-text support: The clearest retrieved subtype statement is: “Type 6 shows mutations in SMAD2,” accompanied by the caution that “LDS type 6 is not consistently used in literature.” (ebeling2024differentiationpurificationand pages 9-11) The I-LoDiS trial record characterizes LDS as a “rare vascular genetic disorder” and describes the broader hypothesis of intracellular TGF-β pathway hyperactivation measured by pSMAD2/3; because that study enrolled receptor-positive LDS, this quote is mechanistically relevant but not direct LDS6 evidence. (NCT05472519 chunk 1)

References

1. (asta2023geneticbasisnew pages 3-5): Laura Asta, Gianluca A. D’Angelo, Daniele Marinelli, and Umberto Benedetto. Genetic basis, new diagnostic approaches, and updated therapeutic strategies of the syndromic aortic diseases: marfan, loeys–dietz, and vascular ehlers–danlos syndrome. International Journal of Environmental Research and Public Health, 20:6615, Aug 2023. URL: https://doi.org/10.3390/ijerph20166615, doi:10.3390/ijerph20166615. This article has 40 citations.

2. (ebeling2024differentiationpurificationand pages 9-11): Differentiation, purification, and characterisation of patient iPSC-derived endothelial cells for Loeys-Dietz-Syndrome disease modelling This article has 1 citations and is from a peer-reviewed journal.

3. (OpenTargets Search: Loeys-Dietz syndrome-SMAD2): Open Targets Query (Loeys-Dietz syndrome-SMAD2, 1 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

4. (zaza2022cleftpalateand pages 2-5): Pierluigi Zaza, Flavia Indrio, Annalisa Fracchiolla, Matteo Rinaldi, Giovanni Meliota, Alessia Salatto, Antonio Bonacaro, and Gianfranco Maffei. Cleft palate and aortic dilatation as clues for loeys–dietz syndrome. Children, 9:1290, Aug 2022. URL: https://doi.org/10.3390/children9091290, doi:10.3390/children9091290. This article has 2 citations.

5. (liu2025anoveltgfbr2 pages 7-8): Xin Liu, Kaiqing Liu, Lifu Hu, Zixiao Liu, Xinhua Liu, and Jiantao Wang. A novel tgfbr2 mutation causes loeys-dietz syndrome in a chinese infant: a case report. Heliyon, Jan 2025. URL: https://doi.org/10.1016/j.heliyon.2025.e42116, doi:10.1016/j.heliyon.2025.e42116. This article has 1 citations.

6. (macfarlane2019lineagespecificeventsunderlie pages 2-5): Elena Gallo MacFarlane, Sarah J. Parker, Joseph Y. Shin, Shira G. Ziegler, Tyler J. Creamer, Rustam Bagirzadeh, Djahida Bedja, Yichun Chen, Juan F. Calderon, Katherine Weissler, Pamela A. Frischmeyer-Guerrerio, Mark E. Lindsay, Jennifer P. Habashi, and Harry C. Dietz. Lineage-specific events underlie aortic root aneurysm pathogenesis in loeys-dietz syndrome. Journal of Clinical Investigation, 129:659-675, Jan 2019. URL: https://doi.org/10.1172/jci123547, doi:10.1172/jci123547. This article has 142 citations and is from a highest quality peer-reviewed journal.

7. (NCT05472519 chunk 1): Immunopathology of Loeys-Dietz Syndrome. Hospices Civils de Lyon. 2022. ClinicalTrials.gov Identifier: NCT05472519

8. (ganizada2024unveilingcellularand pages 14-15): Berta H. Ganizada, Rogier J. A. Veltrop, Asim C. Akbulut, Rory R. Koenen, Ryan Accord, Roberto Lorusso, Jos G. Maessen, Koen Reesink, Elham Bidar, and Leon J. Schurgers. Unveiling cellular and molecular aspects of ascending thoracic aortic aneurysms and dissections. Basic Research in Cardiology, 119:371-395, May 2024. URL: https://doi.org/10.1007/s00395-024-01053-1, doi:10.1007/s00395-024-01053-1. This article has 63 citations and is from a domain leading peer-reviewed journal.

9. (spaziani2024hereditarythoracicaortic pages 7-9): Gaia Spaziani, Francesca Chiara Surace, Francesca Girolami, Francesco Bianco, Valentina Bucciarelli, Francesca Bonanni, Elena Bennati, Luigi Arcieri, and Silvia Favilli. Hereditary thoracic aortic diseases. Diagnostics, 14:112, Jan 2024. URL: https://doi.org/10.3390/diagnostics14010112, doi:10.3390/diagnostics14010112. This article has 7 citations.

10. (asta2023geneticbasisnew pages 5-8): Laura Asta, Gianluca A. D’Angelo, Daniele Marinelli, and Umberto Benedetto. Genetic basis, new diagnostic approaches, and updated therapeutic strategies of the syndromic aortic diseases: marfan, loeys–dietz, and vascular ehlers–danlos syndrome. International Journal of Environmental Research and Public Health, 20:6615, Aug 2023. URL: https://doi.org/10.3390/ijerph20166615, doi:10.3390/ijerph20166615. This article has 40 citations.

11. (NCT01322165 chunk 1): National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions. National Heart, Lung, and Blood Institute (NHLBI). 2007. ClinicalTrials.gov Identifier: NCT01322165

12. (spaziani2024hereditarythoracicaortic pages 9-10): Gaia Spaziani, Francesca Chiara Surace, Francesca Girolami, Francesco Bianco, Valentina Bucciarelli, Francesca Bonanni, Elena Bennati, Luigi Arcieri, and Silvia Favilli. Hereditary thoracic aortic diseases. Diagnostics, 14:112, Jan 2024. URL: https://doi.org/10.3390/diagnostics14010112, doi:10.3390/diagnostics14010112. This article has 7 citations.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.